Navelbine oral,Pembrolizumab

PreclinicalMonoclonal antibody

GGuangzhou Institute of Respiratory Disease

Navelbine oral,Pembrolizumab is one of 38 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

RC148

RRemeGen Co., Ltd.

Phase 3

1 3

Anktiva

SSWOG Cancer Research Network

Phase 3

1 4

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Recruiting·GGuangzhou Institute of Respiratory Disease··NCT06310915·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Navelbine oral,Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Navelbine oral,Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Navelbine oral,Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Institute of Respiratory Disease company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou Institute of Respiratory Disease

Navelbine oral,Pembrolizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News